Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. develops and commercializes treatments for opioid use disorder, with a portfolio centered on long-acting injectable and transmucosal buprenorphine products. The company is headquartered in Richmond, Virginia and sells primarily in the U.S., with a smaller international footprint in Canada, Australia, France, Germany and selected other markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaLong-acting injectable medication used to treat opioid use disorder, anchored by SUBLOCADE.
Sublingual buprenorphine/naloxone film sold mainly in the U.S. through pharmacy channels.
International sales of SUBLOCADE, SUBUTEX Prolonged Release and legacy tablet products.
OPVEE and smaller product lines that are being de-emphasized or supported selectively.
Asiakkaat
Indivior sells mainly into the U.S. healthcare system, where wholesalers, specialty pharmacies and distributors purchase products and then supply pharmacies, hospitals, federal and state entities, and other care settings. The end users are patients being treated for opioid use disorder, while prescribers, health systems and payors influence access, reimbursement and adoption. A few large wholesale customers account for a significant share of revenue, especially for SUBOXONE Film, while specialty pharmacies and distributors are increasingly important as SUBLOCADE grows.
Buy SUBOXONE Film and other products for downstream pharmacy and institutional distribution; they are critical because they represent a concentrated share of revenue.
Purchase and dispense SUBLOCADE under REMS controls, supporting growth as the product shifts toward broader use.
Prescribers and organized health systems choose the therapy based on efficacy, access and administration convenience.
Medicaid, federal programs and 340B-related channels buy or reimburse products and strongly influence net pricing.
Buy products in Canada, Australia, France and Germany, with additional markets being exited or reduced.
Strategia
Indivior’s current strategy is to concentrate resources on its highest-value OUD therapies, especially SUBLOCADE, while simplifying the organization through the Indivior Action Agenda. The company is also rationalizing its Rest of World footprint by exiting lower-priority markets and reducing support for OPVEE, which should lower complexity and operating expense. At the same time, it is investing in manufacturing capacity and maintaining compliance-heavy distribution systems that are central to its regulated business model.
It is the main growth engine and offsets declines in legacy products.
Lower overhead and a leaner structure should improve execution and margins.
Concentrating on higher-return countries reduces complexity and execution risk.
Controlled-substance products require reliable manufacturing, REMS and distribution controls.
Maantiede
The U.S. is Indivior’s core market and accounted for 85% of net revenue in 2025, with the balance coming from Rest of World. International sales are concentrated in Canada, Australia, France and Germany, while the company has announced plans to exit several smaller non-U.S. markets including the U.K., Ireland, Sweden, Israel, Finland and Italy. Manufacturing and supply also matter geographically, including the Fine Chemicals Plant in Hull, U.K. and the Raleigh Manufacturing Facility in the U.S.
Riskit
Indivior’s business is exposed to concentration in SUBLOCADE and to a highly regulated controlled-substance environment, where manufacturing, REMS compliance and payor access can materially affect sales. It also faces pricing pressure from generic competition, government reimbursement risk, litigation and scrutiny of patient assistance programs, all of which can compress net revenue. Internationally, currency and market-exit execution add further volatility to an already concentrated portfolio.
- Dependence on SUBLOCADEVaikutus: KorkeaTodennäköisyys: Korkea
A large share of revenue comes from one product, so any slowdown in adoption, pricing or supply would materially affect results.
Kohdistuu: U.S. OUD treatment market
- Generic and competitive pressure on SUBOXONE FilmVaikutus: KorkeaTodennäköisyys: Korkea
Competition has already reduced category share and pricing, lowering revenue from the legacy oral product.
Kohdistuu: U.S. pharmacy channel
- Reimbursement and Medicaid pricing pressureVaikutus: KorkeaTodennäköisyys: Korkea
Rebates, discounts, best-price rules and payor negotiations directly reduce net revenue.
Kohdistuu: U.S. public and commercial payors
- Regulatory and REMS complianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Products are controlled substances and require certified distribution and strict manufacturing compliance.
Kohdistuu - Litigation and enforcement scrutinyVaikutus: KeskitasoTodennäköisyys: Korkea
The company operates in a sector with elevated legal and regulatory exposure, including patient assistance program scrutiny.
Kohdistuu: U.S. legal and enforcement environment
- Foreign exchange and market exitsVaikutus: KeskitasoTodennäköisyys: Matala
International revenue is smaller but exposed to currency swings and execution risk as markets are exited.
Kohdistuu: Rest of World operations
Kirjanpito
Harkinnanvaraiset erätManagement estimates Medicaid, commercial and prompt-pay deductions using historical and expected future activity; changes can materially alter net revenue.
Vaikutus: Accrued rebates and product returns were $585 million at year-end 2025
U.S. revenue is heavily affected by rebates, discounts and returns, especially for SUBLOCADE growth and channel mix.
Vaikutus: Can change reported revenue growth versus underlying demand
The Action Agenda and market exits create headcount, real estate, consulting and asset impairment costs.
Vaikutus: 2025 charges were significant and expected to lower 2026 operating expense
The company has litigation settlements, debt, supply commitments and contingent value rights that require judgment.
Vaikutus: Can affect liabilities, cash flow and comparability across periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ensysce Biosciences, Inc.
ENSC · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Haleon plc
HLN · Perfumes, Cosmetics & Other Toilet Preparations
Haleon plc is a consumer health company focused on everyday self-care and over-the-counter wellness products.
MannKind Corporation
MNKD · Pharmaceutical Preparations
MannKind Corp is a biopharmaceutical company focused on developing and commercializing inhaled and other specialty therapies, with a commercial base in diabetes and cardiopulmonary care.
Pacira BioSciences, Inc.
PCRX · Pharmaceutical Preparations
Pacira BioSciences is a U.S.-based biopharmaceutical company focused on non-opioid pain management products.
Immunocore Holdings plc
IMCR · Biological Products, (No Diagnostic Substances)
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to…
Päivitetty: 24.9.2026